Cerebrovascular complications of diabetes

Focus on stroke

Adviye Ergul, Aisha Kelly-Cobbs, Maha Abdalla, Susan C. Fagan

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Cerebrovascular complications make diabetic patients 2-6 times more susceptible to a stroke event and this risk is magnified in younger individuals and in patients with hypertension and complications in other vascular beds. In addition, when patients with diabetes and hyperglycemia experience an acute ischemic stroke they are more likely to die or be severely disabled and less likely to benefit from the one FDA-approved therapy, intravenous tissue plasminogen activator. Experimental stroke models have revealed that chronic hyperglycemia leads to deficits in cerebrovascular structure and function that may explain some of the clinical observations. Increased edema, neovascularization and protease expression as well as altered vascular reactivity and tone may be involved and point to potential therapeutic targets. Further study is needed to fully understand this complex disease state and the breadth of its manifestation in the cerebrovasculature.

Original languageEnglish (US)
Pages (from-to)148-158
Number of pages11
JournalEndocrine, Metabolic and Immune Disorders - Drug Targets
Volume12
Issue number2
DOIs
StatePublished - Jun 1 2012

Fingerprint

Diabetes Complications
Stroke
Hyperglycemia
Blood Vessels
Tissue Plasminogen Activator
Edema
Peptide Hydrolases
Theoretical Models
Hypertension
Therapeutics

Keywords

  • Cerebral vasculature
  • Diabetes
  • Hemorrhage
  • Ischemia
  • Stroke
  • Targets

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Immunology and Allergy

Cite this

Cerebrovascular complications of diabetes : Focus on stroke. / Ergul, Adviye; Kelly-Cobbs, Aisha; Abdalla, Maha; Fagan, Susan C.

In: Endocrine, Metabolic and Immune Disorders - Drug Targets, Vol. 12, No. 2, 01.06.2012, p. 148-158.

Research output: Contribution to journalArticle

Ergul, Adviye ; Kelly-Cobbs, Aisha ; Abdalla, Maha ; Fagan, Susan C. / Cerebrovascular complications of diabetes : Focus on stroke. In: Endocrine, Metabolic and Immune Disorders - Drug Targets. 2012 ; Vol. 12, No. 2. pp. 148-158.
@article{754b74fdd6164216b8afc8d94a9f5d67,
title = "Cerebrovascular complications of diabetes: Focus on stroke",
abstract = "Cerebrovascular complications make diabetic patients 2-6 times more susceptible to a stroke event and this risk is magnified in younger individuals and in patients with hypertension and complications in other vascular beds. In addition, when patients with diabetes and hyperglycemia experience an acute ischemic stroke they are more likely to die or be severely disabled and less likely to benefit from the one FDA-approved therapy, intravenous tissue plasminogen activator. Experimental stroke models have revealed that chronic hyperglycemia leads to deficits in cerebrovascular structure and function that may explain some of the clinical observations. Increased edema, neovascularization and protease expression as well as altered vascular reactivity and tone may be involved and point to potential therapeutic targets. Further study is needed to fully understand this complex disease state and the breadth of its manifestation in the cerebrovasculature.",
keywords = "Cerebral vasculature, Diabetes, Hemorrhage, Ischemia, Stroke, Targets",
author = "Adviye Ergul and Aisha Kelly-Cobbs and Maha Abdalla and Fagan, {Susan C.}",
year = "2012",
month = "6",
day = "1",
doi = "10.2174/187153012800493477",
language = "English (US)",
volume = "12",
pages = "148--158",
journal = "Endocrine, Metabolic and Immune Disorders - Drug Targets",
issn = "1871-5303",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Cerebrovascular complications of diabetes

T2 - Focus on stroke

AU - Ergul, Adviye

AU - Kelly-Cobbs, Aisha

AU - Abdalla, Maha

AU - Fagan, Susan C.

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Cerebrovascular complications make diabetic patients 2-6 times more susceptible to a stroke event and this risk is magnified in younger individuals and in patients with hypertension and complications in other vascular beds. In addition, when patients with diabetes and hyperglycemia experience an acute ischemic stroke they are more likely to die or be severely disabled and less likely to benefit from the one FDA-approved therapy, intravenous tissue plasminogen activator. Experimental stroke models have revealed that chronic hyperglycemia leads to deficits in cerebrovascular structure and function that may explain some of the clinical observations. Increased edema, neovascularization and protease expression as well as altered vascular reactivity and tone may be involved and point to potential therapeutic targets. Further study is needed to fully understand this complex disease state and the breadth of its manifestation in the cerebrovasculature.

AB - Cerebrovascular complications make diabetic patients 2-6 times more susceptible to a stroke event and this risk is magnified in younger individuals and in patients with hypertension and complications in other vascular beds. In addition, when patients with diabetes and hyperglycemia experience an acute ischemic stroke they are more likely to die or be severely disabled and less likely to benefit from the one FDA-approved therapy, intravenous tissue plasminogen activator. Experimental stroke models have revealed that chronic hyperglycemia leads to deficits in cerebrovascular structure and function that may explain some of the clinical observations. Increased edema, neovascularization and protease expression as well as altered vascular reactivity and tone may be involved and point to potential therapeutic targets. Further study is needed to fully understand this complex disease state and the breadth of its manifestation in the cerebrovasculature.

KW - Cerebral vasculature

KW - Diabetes

KW - Hemorrhage

KW - Ischemia

KW - Stroke

KW - Targets

UR - http://www.scopus.com/inward/record.url?scp=84861131729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861131729&partnerID=8YFLogxK

U2 - 10.2174/187153012800493477

DO - 10.2174/187153012800493477

M3 - Article

VL - 12

SP - 148

EP - 158

JO - Endocrine, Metabolic and Immune Disorders - Drug Targets

JF - Endocrine, Metabolic and Immune Disorders - Drug Targets

SN - 1871-5303

IS - 2

ER -